# Viking Therapeutics Raises $575M for Obesity Stock

> Viking Therapeutics secured $575 million to fund obesity drug trials and pipeline development.
- Title: Viking Therapeutics Raises $575M for Obesity Stock | Shortify
- Summary: Viking Therapeutics secured $575 million to fund obesity drug trials and pipeline development. Viking Therapeutics raised $575 million to support obesity…
- Keywords: viking therapeutics, vktx, obesity stock, glp-1 agonist, phase 3 trials, convertible senior notes, finance, money, Viking, Therapeutics, Raises, 575M
- Source: The Motley Fool — https://fool.com/investing/2026/10/18/viking-therapeutics-just-raised-575-million-heres
- Author: Lee Samaha
- Published: 2026-10-18T22:30:00+00:00
- Read time: 1 min
- Topics: viking therapeutics, vktx, obesity stock, glp-1 agonist, phase 3 trials, convertible senior notes, finance, money
## Viking Raises $575M
Viking Therapeutics raised $575 million through a stock offering and convertible senior notes.
## Why Cash Is Needed
Viking needs cash to fund large phase 3 trials for its obesity drug VK2735 and pipeline development.
## Trials in Progress
Viking is running 78-week phase 3 trials for VK2735 in obesity and type 2 diabetes with obesity.
## Future Trials Timeline
VK2735 oral trials are expected to conclude in 2028, with results hitting in 2027.
## Key takeaway

Viking Therapeutics raised $575 million to support obesity drug trials and pipeline development.